Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Turk Ilac ve SerumnayiIST:TRILC 61 EV-to-EBIT is 4.37 as of Aug. 09, 2026, which is 58% below its 10-year median of 10.40. GuruFocus rates IST:TRILC with a GF Score™ of 61/100 and a GF Value™ of ₺3.67 (Possible Value Trap). The stock has 11 warning signs investors should review. Among 684 Drug Manufacturers companies, Turk Ilac ve Serumnayi ranks better than 92.4% on this metric.
Turk Ilac ve Serumnayi (IST:TRILC) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Turk Ilac ve Serumnayi's Enterprise Value for the quarter that ended in Sep. 2025 was ₺6,404 Mil.
Turk Ilac ve Serumnayi's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺910 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IST:TRILC vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Turk Ilac ve Serumnayi's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Turk Ilac ve Serumnayi EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Turk Ilac ve Serumnayi's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Turk Ilac ve Serumnayi's EV-to-EBIT falls into.
Turk Ilac ve Serumnayi's current Enterprise Value is ₺3,978 Mil.
Turk Ilac ve Serumnayi's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺910 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Turk Ilac ve Serumnayi (IST:TRILC) has a EV-to-EBIT of 4.37 as of Aug. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Turk Ilac ve Serumnayi and its competitors. This is 58% below median its historical median of 10.40. Over the past decade, Turk Ilac ve Serumnayi's EV-to-EBIT has ranged from 4.32 to 56.69. According to the industry distribution chart, Turk Ilac ve Serumnayi ranks #52 out of 684 companies in the Drug Manufacturers industry, placing it in the top 7.6%.
Is Turk Ilac ve Serumnayi's EV-to-EBIT too high?
Turk Ilac ve Serumnayi's current EV-to-EBIT of 4.37 is 58% below median its 10-year median of 10.40. Over the past 10 years, this metric has ranged from a low of 4.32 to a high of 56.69. The Drug Manufacturers industry median EV-to-EBIT is 15.69. Turk Ilac ve Serumnayi's value of 4.37 is 72.1% below this industry median. Based on the distribution chart, Turk Ilac ve Serumnayi ranks #52 out of 684 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Turk Ilac ve Serumnayi has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Turk Ilac ve Serumnayi's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Turk Ilac ve Serumnayi ranks #52 out of 684 companies for EV-to-EBIT. This places Turk Ilac ve Serumnayi in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.69. Turk Ilac ve Serumnayi's value of 4.37 is 72.1% below this benchmark. Historically, Turk Ilac ve Serumnayi's own EV-to-EBIT has ranged from 4.32 to 56.69 over the past decade. While the company's 10-year median is 10.40 vs. the industry median of 15.69, Turk Ilac ve Serumnayi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.69, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Turk Ilac ve Serumnayi's current EV-to-EBIT of 4.37 is 72.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Turk Ilac ve Serumnayi and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Turk Ilac ve Serumnayi's current EV-to-EBIT is 4.37, which is 58% below median its own 10-year median of 10.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Turk Ilac ve Serumnayi stock overvalued right now?
Based on GuruFocus' analysis, Turk Ilac ve Serumnayi (IST:TRILC) is currently considered Possible Value Trap. The stock's GF Value™ is ₺3.67, compared to a current price of ₺1.20 — trading 67.3% below its estimated fair value. The current EV-to-EBIT is 4.37, which is 58% below median its 10-year median of 10.40 and 72.1% below the Drug Manufacturers industry median of 15.69. Turk Ilac ve Serumnayi's overall GF Score™ is 61/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Turk Ilac ve Serumnayi (IST:TRILC), the current EV-to-EBIT is 4.37 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Turk Ilac ve Serumnayi (IST:TRILC) Overvalued in 2026?
Based on GuruFocus' analysis, Turk Ilac ve Serumnayi stock appears to be undervalued.
The current stock price of ₺1.20 is trading 67.3% below its estimated GF Value™ of ₺3.67.
GuruFocus considers Turk Ilac ve Serumnayi to be Possible Value Trap.
Key valuation signals for IST:TRILC:
EV-to-EBIT: 4.37 (58% below median its 10-year median of 10.40)
GF Value™: ₺3.67 vs. price of ₺1.20 (67.3% below fair value)
Industry Position: 72.1% below the Drug Manufacturers median (#52 of 684)
No single metric tells the full story. See the IST:TRILC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:TRILC has been successfully added to your 
